Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the answer of 17 October 2018 to question 177403 on Cancer: Screening, whether patients and clinicians have access to Oncotype DX despite it not being included in the current version of the National Genomic Test Directory.

Oncotype DX was excluded from the National Tariff from 2016/17 and to support access to it, NHS England entered into arrangements with providers to make this test available. Such arrangements are currently still in place. Since 2016, NHS England has put in place new genomic arrangements and infrastructure and intends to reflect the 2013 National Institute for Health and Care Excellence (NICE) guidelines related to Oncotype DX in the National Genomic Test Directory for cancer. However, it is important to note that the NICE guidance relating to this intervention is under review and once a decision has been made, this information will be considered as part of the regular review and update of the Test Directory.

The National Genomic Test Directory will be updated by NHS England on an annual basis through a clear and transparent process for the future evaluation of new genomic tests.